Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer

Kume,Haruki; Kawai,Taketo; Nagata,Masayoshi; Azuma,Takeshi; Miyazaki,Hideyo; Suzuki,Motofumi; Fujimura,Tetsuya; Nakagawa,Tohru; Fukuhara,Hiroshi; Homma,Yukio

doi:10.3892/mco.2014.469

March-2015 Volume 3 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2015 Volume 3 Issue 2

Full Size Image

Article

Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer

Authors:
- Haruki Kume
- Taketo Kawai
- Masayoshi Nagata
- Takeshi Azuma
- Hideyo Miyazaki
- Motofumi Suzuki
- Tetsuya Fujimura
- Tohru Nakagawa
- Hiroshi Fukuhara
- Yukio Homma
View Affiliations / Copyright

Affiliations: Department of Urology, The University of Tokyo Hospital, Tokyo 113‑8655, Japan
Pages: 303-307
|
Published online on: December 1, 2014

https://doi.org/10.3892/mco.2014.469
Expand metrics +

Abstract

This study was conducted with the aim to investigate the feasibility of intermittent treatment with docetaxel chemotherapy for castration‑resistant prostate cancer (CRPC). A total of 51 men with CRPC received docetaxel at 75 mg̸m2 every 3 weeks combined with oral dexamethasone 1.0‑2.0 mg̸day between 2008 and 2013. The prostate‑specific antigen (PSA) level was monitored every 3 weeks. Chemotherapy was suspended when the serum PSA level decreased to <4 ng̸ml, with a reduction rate of >50% from the baseline. Treatment was resumed when serum PSA increased to >2 ng/ml, with an increase rate of >50% from the nadir. Of the 51 cases, 27 (52.9%) qualified for intermittent treatment; 17 patients received two courses of docetaxel chemotherapy and 10 received three courses. The median off‑treatment interval was 266 days for the first drug holiday, 129.5 days for the second and 146.5 days for the third. The multivariate analysis indicated low baseline PSA (

View Figures

View References

1	http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccess date. 20th–November. 2014
2	http://www.uroweb.org/guidelines/Access date. 20th–November. 2014
3	Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA: Role: TAX 327 InvestigatorsDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
4	Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
5	Naito S, Tsukamoto T, Koga H, Harabayashi T, Sumiyoshi Y, Hoshi S and Akaza H: Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter p hase II trial in Japan. Jpn J Clin Oncol. 38:365–372. 2008. View Article : Google Scholar : PubMed/NCBI
6	Soga N, Kato M, Nishikawa K, Hasegawa Y, Yamada Y, Kise H, Arima K and Sugimura Y: Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. Int J Clin Oncol. 14:130–135. 2009. View Article : Google Scholar : PubMed/NCBI
7	Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J and Henner WDASCENT (AIPC Study of Calcitriol Enhancing Taxotere) Investigators: Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer. 112:326–330. 2008. View Article : Google Scholar : PubMed/NCBI
8	Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Karadimou A, Tsiatas M, Papadimitriou C, Bamias A and Dimopoulos MA: Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology. 77:682–687. 2011. View Article : Google Scholar : PubMed/NCBI
9	The Japanese Urological Association, the Japanese Society of Pathology and Japan Radiological Society, . General rule for Clinical and Pathological Studies on Prostate Cancer. 4th. Kanehara & Co., Ltd.; Tokyo: 2010
10	Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Ishikawa A and Homma Y: Docetaxel as a vital option for corticosteroid-refractory prostate cancer. Int Urol Nephrol. 43:1081–1087. 2011. View Article : Google Scholar : PubMed/NCBI
11	Alken S and Kelly CM: Benefit risk assessment and update on the use of docetaxel in the management of breast cancer. Cancer Manag Res. 5:357–365. 2013.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles